Ritsner Polypharmacy in Psychiatry Practice, Volume II

Use of Polypharmacy in the "Real World"
2013
ISBN: 978-94-007-5799-8
Verlag: Springer Netherland
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 321 Seiten, eBook

Reihe: Biomedical and Life Sciences (R0)

Although monotherapy is generally recommended as the treatment of choice, treatment resistance of patients with psychosis, cognitive, mood and anxiety disorders represents a significant clinical problem. In this context, augmentation and combination strategies are commonly employed to address this problem. Although multiple medication use common in psychiatric practice, reasons, efficacy and safety for polypharmacy, and augmentative strategies have remained unclear. It remains unclear if there is an evidence base to support polypharmacy. Furthermore, excessive and inappropriate use of psychotropic medications has been recognized as a public health problem. This volume is the first comprehensive, clinically oriented, reference on the multiple medication use to treat psychotic, cognitive, mood and anxiety disorders.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Ritsner, Michael S

Inhaltsverzeichnis

About the EditorPreface Contributors to Volume IIPart 1. Antipsychotic polypharmacy  1. Antipsychotic polypharmacy for schizophrenia: 'Secret sauce' or 'wild abandon'? Peter F. Buckley2. Antipsychotic polypharmacy in USA. Anand K. Pandurangi, John Vernon3. Antipsychotic polypharmacy in Czech Republic and in Ukraine. Viktor P. Samokhvalov, Oxana Samokhvalova, Viktoria A. Verbenko, Georgij N. Verbenko4. Antipsychotic polypharmacy in residential facilities in Italy: the gap between recommendations and real world practice. Lucio Ghio, Werner Natta, Simona Gotelli, Luigi Ferrannini5. Antipsychotic polypharmacy and associated phenomena in patients with schizophrenia: Rational or irrational? KH Yong, Norman Sartorius, Kang Sim6. Antipsychotic polypharmacy in schizophrenia. How to counteract this common practice? Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Masaru Mimura 7. Clozapine combinations in treatment-resistant schizophrenia patients. Vladimir Lerner and Chanoch Miodownik8. Metabolic syndrome and antipsychotic polypharmacy. Fuminari Misawa, Fujii Yasuo, Yasuyuki Okumura, Hiroto Ito Part 2. Polypharmacy for other psychiatric conditions9. Evidence based combination therapy for bipolar disorder. Stamatia Magiria, Melina Siamouli, Xenia Gonda, Apostolos Iacovides, Konstantinos N. Fountoulakis10. Antidepressant combination strategies for major depressive disorder. André F. Carvalho, Danielle S. Macêdo, Thomas N. Hyphantis, Roger S. McIntyre11. Herbal remedies and nutraceuticals as augmentation or adjunct for mood and anxiety disorders: evidence for benefit and risk. Arun V. Ravindran and Tricia L. da Silva12. Obsessive-compulsive syndromes in schizophrenia: A case for polypharmacy? Frederike Schirmbeck and Mathias Zink13. Polypharmacy and potentially inappropriate medication use among elders with dementia. Jan Lužný14. The role of polypharmacy in bipolar disorder treatment guidelines. Heinz GrunzeAppendix Rena Kurs1. Annotated bibliography on polypharmacy2. List of Psychotropic Medications  Contents to Volume I Contributors to Volume IIndex